A股異動丨光啟技術(002625.SZ)大漲近8% 公司超材料產品處於滿產狀態
格隆匯7月20日丨光啟技術(002625.SZ)午後急升觸板,現漲7.91%,報10.23元,暫成交6.11億元,最新總市值220億元。光啟技術在互動平台上表示,公司超材料產品主要運用在尖端裝備領域;目前的產能為8噸,處於滿產狀態,隨着順德項目一期年底投產,年底產能預計可以達到48噸。值得注意的是,公司7月17日晚間公告,公司股東俞龍生及其一致行動人擬減持公司股份不超1.29億股,佔公司總股本的6%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.